Cynapsus Therapeutics’ APL-130277 Phase III Study Focus of Presentation

Share

(April 10, 2016) - Cynapsus Therapeutics, currently conducting a pivotal Phase 3 clinical study of its sublingual formulation of apomorphine to treat “OFF” episodes in Parkinson’s disease (PD), is teaming up with the Michael J. Fox Foundation for Parkinson’s Research  for a sub-study that will use wearable technology to gather and analyze patient data on the drug’s effect and disease progression. Read more…

Click for a printer friendly version

Back to top